JP2010504950A5 - - Google Patents

Download PDF

Info

Publication number
JP2010504950A5
JP2010504950A5 JP2009529761A JP2009529761A JP2010504950A5 JP 2010504950 A5 JP2010504950 A5 JP 2010504950A5 JP 2009529761 A JP2009529761 A JP 2009529761A JP 2009529761 A JP2009529761 A JP 2009529761A JP 2010504950 A5 JP2010504950 A5 JP 2010504950A5
Authority
JP
Japan
Prior art keywords
aripiprazole
hours
released
administration
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009529761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504950A (ja
Filing date
Publication date
Priority claimed from GBGB0618879.1A external-priority patent/GB0618879D0/en
Application filed filed Critical
Publication of JP2010504950A publication Critical patent/JP2010504950A/ja
Publication of JP2010504950A5 publication Critical patent/JP2010504950A5/ja
Pending legal-status Critical Current

Links

JP2009529761A 2006-09-26 2007-09-26 医薬組成物 Pending JP2010504950A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0618879.1A GB0618879D0 (en) 2006-09-26 2006-09-26 Pharmaceutical compositions
PCT/GB2007/003677 WO2008038003A2 (en) 2006-09-26 2007-09-26 Pharmaceutical compositions of aripiprazole

Publications (2)

Publication Number Publication Date
JP2010504950A JP2010504950A (ja) 2010-02-18
JP2010504950A5 true JP2010504950A5 (https=) 2010-12-09

Family

ID=37421592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529761A Pending JP2010504950A (ja) 2006-09-26 2007-09-26 医薬組成物

Country Status (13)

Country Link
US (2) US8575172B2 (https=)
EP (1) EP2066325B1 (https=)
JP (1) JP2010504950A (https=)
KR (1) KR20090065514A (https=)
AT (1) ATE540680T1 (https=)
AU (1) AU2007301742B2 (https=)
CA (1) CA2664455A1 (https=)
DK (1) DK2066325T3 (https=)
ES (1) ES2395119T3 (https=)
GB (1) GB0618879D0 (https=)
IL (1) IL197574A (https=)
PT (1) PT2066325E (https=)
WO (1) WO2008038003A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
PL2317852T3 (pl) 2008-07-16 2015-05-29 Richter Gedeon Nyrt Preparaty farmaceutyczne zawierające ligandy receptora dopaminy
US8372808B2 (en) * 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
US8815261B2 (en) 2009-06-19 2014-08-26 Medrx Co., Ltd. Composition for external application comprising aripiprazole and organic acid as active ingredients
CN102670553A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 盐酸文拉法辛渗透泵控释片
WO2012129232A1 (en) * 2011-03-21 2012-09-27 Conour James Compositions for the treatment of psychotic or neurological disorders
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
CA2905501A1 (en) * 2013-03-15 2014-09-18 Ameritox, Ltd. Methods of monitoring for adherence to aripiprazole therapy
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
CN103536594A (zh) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
US20190070174A1 (en) * 2016-03-10 2019-03-07 The Regents Of The University Of Michigan Methods of treating neurodegenerative diseases
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CN110025572A (zh) * 2018-01-11 2019-07-19 四川科伦药物研究院有限公司 月桂酰阿立哌唑混悬剂及其制备方法
ES2991518T3 (es) * 2018-05-04 2024-12-03 Korea Inst Radiological & Medical Sciences Composición para la mejora de la sensibilidad a la radiación que contiene aripiprazol como ingrediente activo
US12138363B2 (en) * 2018-10-04 2024-11-12 École Polytechnique Fédérale de Lausanne Cross-linkable polymer, hydrogel, and method of preparation thereof
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
JP2024502431A (ja) * 2020-12-31 2024-01-19 レイク オハラ エルエルシー 肥満患者における、ブレクスピプラゾールを用いた精神疾患の治療方法
KR102525213B1 (ko) 2021-01-13 2023-04-25 아주대학교산학협력단 Qr 코드가 적용된 구강붕해필름 및 3d 프린팅 기술을 이용한 이의 제조방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JP2004517112A (ja) 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
EA009780B1 (ru) 2001-06-19 2008-04-28 Норберт Мюллер Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
JP2006505489A (ja) 2002-02-08 2006-02-16 アボット・ラボラトリーズ 精神分裂病の治療のための併用療法
EP1491207A4 (en) * 2002-03-28 2006-02-08 Takeda Pharmaceutical NEW SCREENING PROCESS
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
AU2003259256A1 (en) 2002-07-29 2004-02-16 Potomac Pharma, LLC. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
CA2495864C (en) 2002-08-20 2011-09-27 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
WO2004083183A1 (en) 2003-03-21 2004-09-30 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
WO2005048979A2 (en) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
DE10353196A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
CA2547639A1 (en) 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
CA2550726A1 (en) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
JP2007519705A (ja) 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
BRPI0510942A (pt) 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
WO2006000222A2 (en) 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
WO2006012237A2 (en) 2004-06-25 2006-02-02 Shanghai Institute Of Pharmaceutical Industry Aripiprazole crystaline forms and associated methods
GB0417702D0 (en) 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
WO2006053780A1 (en) 2004-11-18 2006-05-26 Synthon B.V. Crystalline aripiprazole solvates
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006097344A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
WO2007004061A1 (en) 2005-04-15 2007-01-11 Medichem, S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
HUP0500683A3 (en) 2005-07-14 2009-03-30 Egis Gyogyszergyar Nyilvanosan New arylpiprazole salts for producing pharmaceutical composition
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
PT1808164E (pt) 2006-01-05 2009-03-17 Teva Pharma Método de granulação húmida para a preparação de composições farmacêuticas de aripiprazole
DE602006006536D1 (de) 2006-01-05 2009-06-10 Teva Pharma Trockene Aripiprazolformulierungen
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2010504950A5 (https=)
Dell’Osso et al. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects
Cardinali et al. Melatonin and its analogs in insomnia and depression
López-Muñoz et al. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders
CN1832734B (zh) 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘
WO2022256720A2 (en) Enantiomeric entactogen compositions and methods of their use
JP2010523640A5 (https=)
US20130281523A1 (en) Low dose cannabinoid medicaments
Saini et al. Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review
CN115521217A (zh) 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法
JP7245509B2 (ja) 吃音を治療するための融合ベンズアゼピン
EP2007369A2 (en) Use of rasagiline for the treatment of restless legs syndrome
CN114340670A (zh) T-型钙通道调节剂的制剂及其使用方法
JP2017534613A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
Strecker et al. Parkinson's disease: emerging pharmacotherapy
PT1745786E (pt) Compostos neuroprotetores e composições farmacêuticas que os compreendem
WO2015153971A1 (en) Methods of treating sleep disorders associated with neurodegenerative diseases
Nishino Modes of action of drugs related to narcolepsy: pharmacology of wake-promoting compounds and anticataplectics
Dhawan et al. Auvelity: A new era in medicine-unraveling the multifaceted benefits of dextromethorphan/bupropion combination
US20060217394A1 (en) Treatment of anhedonia
JP2022511755A (ja) 精神障害の治療のためのガボキサドールとリチウムとの組み合わせ
Tremor The Underrecognized Movement Disorders Associated With Mood Stabilizers
CN111670041A (zh) 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
Wilson Pharmacology of psychiatric drugs and their effects on sleep
ES2969657T3 (es) Tratamiento de trastorno de síndrome postraumático